Which drug is indicated for the treatment of both Prostate Cancer and other conditions?

Zytiga, also known by its generic name abiraterone acetate, is indicated for the treatment of prostate cancer, particularly castration-resistant prostate cancer. In addition to its primary use for prostate cancer, Zytiga is also being investigated and used in conjunction with other treatments for conditions related to hormone-sensitive prostate cancer.

Zytiga works by inhibiting an enzyme involved in the production of androgens, which can fuel cancer growth. By lowering androgen levels in the body, it effectively helps in managing prostate cancer progression.

Other drugs listed have specific indications that do not overlap with prostate cancer. Sovaldi, for example, is primarily used for the treatment of hepatitis C, while Gleevec is utilized for certain types of leukemia and gastrointestinal stromal tumors. Tecfidera is indicated for the treatment of multiple sclerosis. None of these alternatives address prostate cancer, confirming Zytiga as the appropriate choice for both prostate cancer treatment and potential additional applications in related conditions.